

No	Subject	Document date	Register number	Release? YES/Partial/NO/Public	Reason/Exception (*) (if no/partial release)
1	Stakeholders meeting about introducing changes to ongoing clinical trials (Call with european	14-09-20	Ares(2020)4878235	Partial	personal data Art 4 (1) b
2	Complex clinical trials meeting with stakeholders	16-09-20	Ares(2020)4900196	Partial	personal data Art 4 (1) b
3	Discussion with EFPIA	23-09-20	Ares(2021)1425931	Partial	personal data Art 4 (1) b
4	Meeting with the European Commission Japan-EU MRA and EPA	28-09-20	Ares(2021)598108	Partial	personal data Art 4 (1) b
4 bis	Meeting with the European Commission Japan-EU MRA and EPA_ presentation	28-09-20	Ares(2021)598108	No release	commercial interest, Art 4 (2), first indent
5	Commissioner Kyriakides/ Breton call with supply chain stakeholders	30-09-20	Ares(2020)5299706	Partial	personal data Art 4 (1) b + out of scope
6	CAB joint meeting with EFPIA and MfE on COVID-19 lessons learnt and pharmaceutical strategy	22-10-20	Ares(2020)6134457	Partial	personal data Art 4 (1) b + out of scope
7	Meeting with EFPIA to discuss the implementation of FMD due to Brexit	02-10-20	Ares(2021)2195564	Partial	personal data Art 4 (1) b
7 bis	Meeting with EFPIA to discuss the implementation of FMD due to Brexit- attachment	02-10-20	Ares(2021)2195564	Partial	personal data Art 4 (1) b
8	Meeting Commissioners Kyriakides/ Breton with supply chain stakeholders 6 November 2020	06-10-20	Ares(2020)7303583	Partial	personal data Art 4 (1) b + out of scope
9	EFPIA-EFGCPP lay summary initiative	12-11-20	Ares(2021)1409906	Partial	personal data Art 4 (1) b
9 bis	EFPIA-EFGCPP lay summary initiative- attachments	12-11-20	Ares(2021)1409906	Partial	personal data Art 4 (1) b
10	Meeting with the stakeholder group on complex trials	13-11-20	Ares(2021)1409089	Partial	personal data Art 4 (1) b
11	EFPIA surevy of the Covid19 clincial trials guidance	09-12-20	Ares(2021)340868	Partial	personal data Art 4 (1) b
12	BTO on structured dialogue scoping meeting	18-01-21	Ares(2021)595841	Partial	personal data Art 4 (1) b
13	Meeting with stakeholders to discuss substantial modifications in clinical trials	18-01-21	Ares(2021)499724	Partial	personal data Art 4 (1) b
13 bis	Meeting with stakeholders to discuss substantial modifications in clinical trials - attachment 1	18-01-21	Ares(2021)499724	Full	
13 ter	Meeting with stakeholders to discuss substantial modifications in clinical trials - attachment 2	18-01-21	Ares(2021)499724	Partial	personal data Art 4 (1) b
14	Stakeholder/EMA /EC meeting in the margin of IWG	22-01-21	Ares(2021)902207	Partial	personal data Art 4 (1) b
15	Meeting with EFPIA representatives for the BREXIT Issues	05-02-21	Ares(2021)1127107	Partial	personal data Art 4 (1) b
15 bis	Meeting with EFPIA representatives for the BREXIT Issues - attachment	05-02-21	Ares(2021)1127107	Full	
16	Phone call with EFPIA	12-02-21	Ares(2021)1462552	Partial	personal data Art 4 (1) b
17	Minutes of meeting with Vaccines Europe- regulatory issues regarding COVID-19 vaccines -18 September 2020	26-02-21	Ares(2021)1511032	Partial	personal data Art 4 (1) b
18	BTO - 2 October 2020 Video-call on pharmaceutical related issues - Directorate B and EFPIA (European Federation of Pharmaceutical Industries and Associations)	26-02-21	Ares(2021)1508931	Partial	personal data Art 4 (1) b
19	BTO - virtual meeting with Efpia on revision of variation framework 23 February 2021	23-02-21	Ares(2021)1436194	Partial	personal data Art 4 (1) b
20	BTO meeting EFPIA 13 January 2021 about revision O/P legislation	25-01-21	Ares(2021)608036	Partial	personal data Art 4 (1) b
21	RE: Request for a meeting- regulatory issues regarding COVID-19 vaccines	11-09-20	Ares(2020)4762652	Partial	personal data Art 4 (1) b
22	RE: Vaccines Europe CMC document	07-10-20	Ares(2020)5302301	Partial	personal data Art 4 (1) b
22 bis	RE: Vaccines Europe CMC document - attachment	07-10-20	Ares(2020)5302301	Full	personal data Art 4 (1) b
23	BTO meeting with EFPIA yesterday - also in view of our meeting	16-12-20	Ares(2020)7655109	Partial	personal data Art 4 (1) b
24	RE: VE position on a revision of the Annex to the EC guideline on “Excipients in the labelling and package leaflet of medicinal products for human use”	15-12-20	Ares(2020)7621300	Partial	personal data Art 4 (1) b
25	VE position on a revision of the Annex to the EC guideline on “Excipients in the labelling and package leaflet of medicinal products for human use”	15-12-20	Ares(2020)6424812	Partial	personal data Art 4 (1) b
25 bis	VE position on a revision of the Annex to the EC guideline on “Excipients in the labelling and package leaflet of medicinal products for human use”- attachment	15-12-20	Ares(2020)6424812	Full	
26	Fwd: Kind request for a meeting - European Commission	12-10-20	Ares(2020)5587942	Partial	personal data Art 4 (1) b
27	Letter on packaging and labelling flexibilities for COVID-19 therapeutics	12-20-2020	Ares(2020)7464492	Partial	personal data Art 4 (1) b
27 bis	Letter on packaging and labelling flexibilities for COVID-19 therapeutics- attachment	12-20-2020	Ares(2020)7464492	Partial	personal data Art 4 (1) b
28	[Re] Letter on packaging and labelling flexibilities for COVID-19 therapeutics	11-01-21	Ares(2021)211520	Partial	personal data Art 4 (1) b
29	RE: Letter on packaging and labelling flexibilities for COVID-19 therapeutics	08-02-21	Ares(2021)1089908	Partial	personal data Art 4 (1) b
30	Discussion with EFPIA	23.09.2020	Ares(2020)5010072	Partial	personal data Art 4 (1) b
31	Meeting with industry to seek for leadership on Covid-19 planning for a second wave risk + transmission of presentations	25-09-20	Ares(2020)5040516	Partial	personal data Art 4 (1) b
31 bis	Meeting with industry to seek for leadership on Covid-19 planning for a second wave risk + transmission of presentations- attachment 1	25-09-20	Ares(2020)5040516	Partial	personal data Art 4 (1) b
31 ter	Meeting with industry to seek for leadership on Covid-19 planning for a second wave risk + transmission of presentations-attachment 2	25-09-20	Ares(2020)5040516	Partial	personal data Art 4 (1) b

31 quater	Meeting with industry to seek for leadership on Covid-19 planning for a second wave risk + transmission of presentations- attachment 3	25-09-20	Ares(2020)5040516	Full	
31 quinquies	Meeting with industry to seek for leadership on Covid-19 planning for a second wave risk + transmission of presentations- attachment 4	25-09-20	Ares(2020)5040516	Full	
32	[Re] Meeting with industry to seek for leadership on Covid-19 planning for a second wave risk + transmission of presentations	27-09-20	Ares(2020)5058657	Partial	personal data Art 4 (1) b
33	THANK YOU note (European Federation of Pharmaceutical Industries and Associations) for the regular phone calls in relation with the sanitary crisis and report (EFPIA & Vaccines Europe) relating the situational analysis (latest update 30/09/2020)	02-10-20	Ares(2020)5191240	Partial	personal data Art 4 (1) b
33 bis	THANK YOU note (European Federation of Pharmaceutical Industries and Associations) for the regular phone calls in relation with the sanitary crisis and report (EFPIA & Vaccines Europe) relating the situational analysis (latest update 30/09/2020)- attachment	02-10-20	Ares(2020)5191240	Full	
34	EFPIA COVID-19 Situational assessment to 6 October 2020	08-10-20	Ares(2020)5352876	Partial	personal data Art 4 (1) b
34 bis	EFPIA COVID-19 Situational assessment to 6 October 2020- attachment	08-10-20	Ares(2020)5352876	Full	
35	Letter on Pharmaceutical Strategy from EFPIA and Medicines for Europe following up from constructive exchange of views together with an accompanying technical article related to the letter	28-10-20	Ares(2020)6036838	Partial	personal data Art 4 (1) b
35 bis	Letter on Pharmaceutical Strategy from EFPIA and Medicines for Europe following up from constructive exchange of views together with an accompanying technical article related to the letter- attachment 1	28-10-20	Ares(2020)6036838	Partial	personal data Art 4 (1) b
35 tris	Letter to Head of Cabinet on Pharmaceutical Strategy from EFPIA and Medicines for Europe following up from constructive exchange of views together with an accompanying technical article related to the letter- attachment 2	28-10-20	Ares(2020)6036838	Partial	personal data Art 4 (1) b
36	RE: Thank you for speaking at the EU Health Summit	29-10-20	Ares(2020)6116647	Partial	personal data Art 4 (1) b
37	Call 2: EFPIA & Vaccines Europe follow-up to 6 November 2020 videocall on COVID-19	11-11-20	Ares(2020)6600645	Partial	personal data Art 4 (1) b
38	EFPIA COVID-19 Situational assessment to 29 January 2021	01-02-21	Ares(2021)851702	Partial	personal data Art 4 (1) b
38bis	EFPIA COVID-19 Situational assessment to 29 January 2021- attachment	01-02-21	Ares(2021)851702	Full	
39	Release of pubblication with situational assessment on Covid-19 from EFPIA	03-02-21	Ares(2021)931831	Partial	personal data Art 4 (1) b
39 bis	Release of pubblication with situational assessment on Covid-19 from EFPIA- attachment	03-02-21	Ares(2021)931831	Full	
40	JOINT letter - Business Europe - EFPIA - Medicines for Europe - request for a dialogue on the EU vaccines export authorisation scheme	14-02-21	Ares(2021)1240510	Partial	personal data Art 4 (1) b
40 bis	JOINT letter - Business Europe - EFPIA - Medicines for Europe - request for a dialogue on the EU vaccines export authorisation scheme - attachment	14-02-21	Ares(2021)1240510	Partial	personal data Art 4 (1) b
41	Release from EFPIA on impact of the COVID-19 outbreak on the supply of medicines in the Union/EEA	22-02-21	Ares(2021)1403162	Partial	personal data Art 4 (1) b
41bis	Release from EFPIA on impact of the COVID-19 outbreak on the supply of medicines in the Union/EEA- attachment	22-02-21	Ares(2021)1403162	Full	
42	Meeting with EFPIA, Medicines for Europe and Business Europe - 5 March 2021	08-03-21	Ares(2021)1684811	Partial	personal data Art 4 (1) b
(*)	Indicates applicable exception in Art. 4 of Regulation (EC) 1049/2001				